Out to prove the next big I/O target, Immunitas' chief dealmaker steps up to CEO role
To Amanda Wagner, the past two years or so she’s spent at Immunitas feels like a microcosm of her entire career up to now.
Trained in neuroscience and equipped with an MBA, Wagner’s 16-year biopharma career could be split into a first half in R&D and a second in corporate finance and business development. She was consulting for the Longwood Fund in 2019 when the VC firm pulled her aside to talk about a new immuno-oncology company it was incubating.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.